Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total value of $87,455.08. Following the transaction, the director now owns 7,066,113 shares in the company, valued at $53,985,103.32. The trade was a 0.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Blake Borgeson also recently made the following trade(s):
- On Tuesday, October 29th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.72, for a total transaction of $76,923.84.
- On Tuesday, October 15th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.67, for a total transaction of $76,351.49.
- On Tuesday, October 1st, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.22, for a total value of $71,200.34.
- On Tuesday, September 17th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.84, for a total value of $78,297.48.
- On Tuesday, September 3rd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.27, for a total value of $71,772.69.
- On Tuesday, August 20th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.12, for a total transaction of $81,502.64.
Recursion Pharmaceuticals Price Performance
My #1 Pre IPO Trade for 2025 – NAME and TICKER
From Wyatt Investment Research | Ad
One tiny company...
Could quickly become "the next SpaceX."
It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00.
Get urgent details inside this free report...
The Next SpaceX Pre-IPO
Shares of NASDAQ:RXRX traded down $0.54 during trading on Friday, hitting $6.37. 2,818,972 shares of the company were exchanged, compared to its average volume of 5,717,881. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 1-year low of $5.89 and a 1-year high of $15.74. The company has a market capitalization of $1.79 billion, a P/E ratio of -4.18 and a beta of 0.81. The business's 50 day moving average is $6.65 and its 200-day moving average is $7.61.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.01). The firm had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals's revenue for the quarter was up 147.6% on a year-over-year basis. During the same period in the previous year, the company earned ($0.43) EPS. Equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.
Institutional Investors Weigh In On Recursion Pharmaceuticals
Institutional investors have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC acquired a new position in shares of Recursion Pharmaceuticals during the third quarter worth $25,000. Farther Finance Advisors LLC raised its position in Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock worth $42,000 after purchasing an additional 4,091 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company's stock worth $48,000 after buying an additional 6,036 shares during the period. Amalgamated Bank grew its position in shares of Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company's stock valued at $54,000 after buying an additional 2,459 shares during the last quarter. Finally, KBC Group NV increased its stake in shares of Recursion Pharmaceuticals by 79.9% in the third quarter. KBC Group NV now owns 7,602 shares of the company's stock valued at $50,000 after buying an additional 3,377 shares during the period. 89.06% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Several analysts recently issued reports on RXRX shares. Leerink Partners reduced their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating on the stock in a research report on Tuesday, September 3rd. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, November 7th. Finally, Jefferies Financial Group dropped their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating for the company in a research report on Tuesday, September 3rd. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $9.25.
Get Our Latest Stock Report on RXRX
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
